- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02524717
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
17. května 2019 aktualizováno: Aragon Pharmaceuticals, Inc.
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Subjects With Mild or Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
The purpose of this study is to characterize the pharmacokinetics of JNJ-56021927 in participants with mild and moderate hepatic impairment.
Přehled studie
Detailní popis
This is an open-label (all people know the identity of the intervention), single-dose, single-center, non-randomized study of JNJ-56021927 in participants who either have hepatic impairment or qualify for the control group.
The study consists of 3 Phases: Screening Phase (21 Days), open-label treatment Phase (8 Days) and follow up Phase (49 Days).
The duration of participation in the study for each participant is approximately 78 Days.
Primarily the pharmacokinetics of JNJ-56021927 will be measured.
Participants' safety will be monitored throughout the study.
Typ studie
Intervenční
Zápis (Aktuální)
24
Fáze
- Fáze 1
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Tennessee
-
Knoxville, Tennessee, Spojené státy
-
-
Texas
-
San Antonio, Texas, Spojené státy
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let až 80 let (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Mužský
Popis
Inclusion Criteria:
- Must have a clinically stable hepatic function as confirmed by the serum bilirubin and transaminase levels measured during Screening and those measured within 24 hours prior to study drug administration
- Sign an informed consent document indicating that the participant understands the purpose of and procedures required for the study and are willing to participate in the study. Participants must not have hepatic encephalopathy greater than or equal to (>=) Grade 3 where the participant lacks the capacity to provide informed consent as judged by the investigator. Mild or moderate hepatic encephalopathy that would not impede informed consent in the investigator's judgment is permitted
- Willing and able to adhere to the prohibitions and restrictions as specified in the protocol
- If a man is sexually active with a woman of childbearing potential and has not had a vasectomy, he must agree to use an adequate contraception method as deemed appropriate by the Investigator, always use a condom during sexual intercourse, and agree to not donate sperm during the study and for 3 months after receiving the study drug
- Body mass index (BMI) between 18 and 35 kilogram (kg)/meter (m)^2 (inclusive), and body weight not less than 50 kg
- The participant must have a total Child-Pugh score of 5 to 6, inclusive (mild); or 7 to 9, inclusive (moderate); the investigator will determine hepatic impairment
Exclusion Criteria:
- Screening thyroid-stimulating hormone (TSH) level greater than (>) Upper Limit of Normal (ULN), or participants with known history of thyroid disorders
- Participant who is on thyroid replacement therapy
- History of drug abuse according to Diagnostic and Statistical Manual of Mental Disorders (4th edition) (DSM-IV) criteria within 2 years before Screening or positive test result(s) for drugs of abuse (that is, opiates, barbiturates, benzodiazepines, cocaine, cannabinoids, and amphetamines) at Screening or Day -1. A positive test for participants with prescriptions for drugs that may interfere with the drug screen (that is, opiates and benzodiazepines) may be allowed
- Known allergy to the study drug or any of the excipients of the formulation
- Intention to donate blood or blood products during the study or for 3 months after the administration of the study drug
- A man who plans to father a child while enrolled in the study or for 3 months after receiving the study drug
- Known history of seizure or condition that may predispose to seizure or on medication that lowers seizure threshold
- History of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs
- Gall bladder (example, cholecystitis and cholelithiasis) or biliary tract disease
- Clinically significant renal laboratory findings including serum creatinine level greater than (>) 1.5 times ULN
- Inability to fast for 12 hours
- History of or current clinically significant medical illness
- Positive test for human immunodeficiency virus (HIV) 1 and 2 antibodies
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: JNJ-56021927
Participants with mild and moderate hepatic impairment and with normal hepatic function will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
|
Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Maximum Plasma Concentration (Cmax) of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The Cmax is the maximum observed plasma concentration of JNJ-56021927.
|
Pre-dose up to 1344 hours post-dose
|
Maximum Plasma Concentration Corrected for Unbound Fraction (Cmax_unb) of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The Cmax_unb is the maximum observed plasma concentration corrected for unbound fraction of JNJ-56021927.
|
Pre-dose up to 1344 hours post-dose
|
Time to Reach the Maximum Plasma Concentration (Tmax) of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The Tmax is the time to reach the maximum observed plasma concentration of JNJ-56021927.
|
Pre-dose up to 1344 hours post-dose
|
Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC[0-24]) Post Dose of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The AUC(0-24hrs) is the area under the plasma concentration-time curve from 0 to 24 hours post dosing.
|
Pre-dose up to 1344 hours post-dose
|
Area Under the Plasma Concentration-Time Curve From 0 to 168 Hours (AUC[0-168]) Post Dose of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The AUC(0-168hrs) is the area under the plasma concentration-time curve from 0 to 168 hours post dosing.
|
Pre-dose up to 1344 hours post-dose
|
Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration (AUC[0-last]) Post Dose of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The AUC(0-last) is the area under the plasma concentration-time curve from 0 to time of the last quantifiable concentration.
|
Pre-dose up to 1344 hours post-dose
|
Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration Corrected for Unbound Fraction (AUC[last_unb]) Post Dose of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The AUC(last_unb) corrected for unbound fraction is the area under the plasma concentration-time curve from 0 to time of the last quantifiable concentration.
|
Pre-dose up to 1344 hours post-dose
|
Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity]) Post Dose of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The AUC (0-infinity) is the area under the plasma JNJ-56021927 concentration-time curve from time 0 to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z), in which AUC(0-last) is area under the plasma JNJ-56021927 concentration-time curve from time zero to time of the last quantifiable concentration, C(last) is the last observed quantifiable concentration and lambda(z) is elimination rate constant.
|
Pre-dose up to 1344 hours post-dose
|
Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time Corrected for Unbound Fraction (AUC[infinity_unb]) Post Dose of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The AUC(infinity_unb) is the area under the plasma JNJ-56021927 concentration-time curve from time 0 to infinite time corrected for unbound fraction, calculated as the sum of AUC (0-last) and C(last)/lambda(z), in which AUC(0-last) is area under the plasma JNJ-56021927 concentration-time curve from time zero to time of the last quantifiable concentration, C(last) is the last observed quantifiable concentration and lambda(z) is elimination rate constant.
|
Pre-dose up to 1344 hours post-dose
|
Percentage of Area Under the Plasma Concentration-Time Curve Obtained by Extrapolation (%AUC[infinity,ex])
Časové okno: Pre-dose up to 1344 hours post-dose
|
The %AUC[infinity,ex] is calculated by dividing the difference of AUC(0-infinity) and AUC(0-last) by AUC(0-infinity) and then multiplying by 100, (AUC[0-infinity] - AUC[0-last])*100/AUC[0-infinity].
|
Pre-dose up to 1344 hours post-dose
|
Terminal Half-life (t[1/2]) of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
Elimination half-life associated with the terminal slope Lambda (z) of the semi logarithmic drug concentration-time curve, calculated as 0.693/Lambda (z).
|
Pre-dose up to 1344 hours post-dose
|
Elimination Rate Constant (Lambda [z]) of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The Lambda (z) determined by first-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.
|
Pre-dose up to 1344 hours post-dose
|
Time of Last Measurable Plasma Concentration (Tlast) of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
Time to last measurable plasma concentration is evaluated.
|
Pre-dose up to 1344 hours post-dose
|
Total Apparent Clearance (CL/F) of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The CL/F is defined as Dose/AUC (0-infinity).
|
Pre-dose up to 1344 hours post-dose
|
Apparent Volume of Distribution (Vd/F) of JNJ-56021927
Časové okno: Pre-dose up to 1344 hours post-dose
|
The Vd/F is defined as Dose/[Lambda (z)*AUC (0-infinity)].
|
Pre-dose up to 1344 hours post-dose
|
Metabolite to Parent Drug Ratio for Maximum Observed Plasma Concentration (MPR Cmax)
Časové okno: Pre-dose up to 1344 hours post-dose
|
The (MPR Cmax) is metabolite to parent drug ratio for maximum observed plasma concentration.
|
Pre-dose up to 1344 hours post-dose
|
Metabolite to Parent Drug Ratio for Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Quantifiable Concentration (MPR AUC[0-last])
Časové okno: Pre-dose up to 1344 hours post-dose
|
The MPR AUClast is metabolite to parent drug ratio for area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUC [0-last]).
|
Pre-dose up to 1344 hours post-dose
|
Metabolite to Parent Drug Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (MPR AUC [0-infinity])
Časové okno: Pre-dose up to 1344 hours post-dose
|
The MPR AUC [0-infinity] is metabolite to parent drug ratio for area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUC [0-infinity]).
|
Pre-dose up to 1344 hours post-dose
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Number of Participants with Adverse Events (AEs) and Serious AEs
Časové okno: Screening up to follow-up (56 days after dose administration)
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Screening up to follow-up (56 days after dose administration)
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
13. srpna 2015
Primární dokončení (Aktuální)
9. února 2017
Dokončení studie (Aktuální)
9. února 2017
Termíny zápisu do studia
První předloženo
13. srpna 2015
První předloženo, které splnilo kritéria kontroly kvality
13. srpna 2015
První zveřejněno (Odhad)
17. srpna 2015
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
21. května 2019
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
17. května 2019
Naposledy ověřeno
1. května 2019
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CR107774
- 56021927PCR1018 (Jiný identifikátor: Janssen Research & Development, LLC)
Informace o lécích a zařízeních, studijní dokumenty
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na JNJ-56021927
-
Janssen Pharmaceutical K.K.Dokončeno
-
Aragon Pharmaceuticals, Inc.Dokončeno
-
Janssen Research & Development, LLCNáborPoškození jaterSpojené státy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktivní, ne náborAdenokarcinom prostaty | Etapa IIB rakoviny prostaty AJCC v8Spojené státy
-
University of WashingtonNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCUkončenoAdenokarcinom prostatySpojené státy
-
National Cancer Institute (NCI)NáborAdenokarcinom prostaty | Lokalizovaný karcinom prostaty | Fáze I rakoviny prostaty AJCC v8 | Fáze II rakoviny prostaty AJCC v8Spojené státy
-
Janssen Pharmaceutical K.K.DokončenoBezpečnostní studie JNJ-56021927 u účastníků s metastatickou kastrací rezistentní rakovinou prostatyNovotvary prostaty, odolné proti kastraciJaponsko
-
Aragon Pharmaceuticals, Inc.Již není k dispoziciNovotvary prostatyKolumbie, Brazílie, Mexiko
-
Janssen Research & Development, LLCAktivní, ne nábor
-
National Cancer Institute (NCI)Zatím nenabírámeNesvalový invazivní uroteliální karcinom močového měchýře | Recidivující nesvalový invazivní uroteliální karcinom močového měchýřeSpojené státy